4th International Conference on Thoracic Oncology

Oncology Meeting Resources

26 Jun - 28 Jun, Rome, Italy

This conference favours the multidisciplinary approach involving all professional disciplines (medical oncologists, pneumologists, thoracic surgeons, radiotherapists, radiologists, and others) who play an important part in the field of thoracic oncology.

The presenters have made webcasts and PDF versions of presentations available to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful links

Presenter Presentation title Session title
F. de Marinis Introduction Welcome Lecture
T. Mok IASLC and new horizons in the battle against lung cancer Welcome Lecture
L. Spaggiari Pro surgery Face to face I - Treatment of initially unresectable locally advanced NSCLC: Neoadjuvant chemotherapy plus surgery vs definitive chemo-radiotherapy
J. van Meerbeeck Pro radiotherapy Face to face I - Treatment of initially unresectable locally advanced NSCLC: Neoadjuvant chemotherapy plus surgery vs definitive chemo-radiotherapy
M. Garcia Lecture I - New development in mutation detection Opening ceremony
F. A. Shepherd Erlotinib Special symposium I - Treatment of NSCLC with activating EGFR mutation: Who is the better?
T. Mok Gefitinib Special symposium I - Treatment of NSCLC with activating EGFR mutation: Who is the better?
J. Yang Afatinib Special symposium I - Treatment of NSCLC with activating EGFR mutation: Who is the better?
A. Ardizzoni Old platin-based chemotherapy Advanced NSCLC and not biomarker-driven treatment: Debating in the first-line treatment arena
L. Paz-Ares Pemetrexed Advanced NSCLC and not biomarker-driven treatment: Debating in the first-line treatment arena
B. Besse Bevacizumab Advanced NSCLC and not biomarker-driven treatment: Debating in the first-line treatment arena
M. Garcia ALK detection from FISH to IHC Special symposium II - Treatment of NSCLC with ALK genetic alteration
F. Hirsch Crizotinib Special symposium II - Treatment of NSCLC with ALK genetic alteration
S. Novello LDK 378 and others Special symposium II - Treatment of NSCLC with ALK genetic alteration
F. A. Shepherd The evolving treatment landscape of NSCLC Satellite Lecture: AstraZeneca: Open questions in NSCLC EGFR+ treatment